Hyperlipoproteinemia causes: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 359: Line 359:


====High Triglyceride Causes====
====High Triglyceride Causes====
{{col-begin|width=80%}}
{{col-break|width=33%}}
*[[Acute pancreatitis]]
*[[Alagille syndrome]]
*[[Alcohol]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Alström syndrome]]
*[[Amprenavir]]
*[[apolipoprotein E|Apoprotein E deficiency]]
*[[atazanavir|Atazanavir sulfate]]
*[[Atypical antipsychotics]]
*[[Bendrofluazide]]
*[[Beta-blockers]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Bexarotene]]
*[[Carnitine palmitoyltransferase 1 deficiency]]
*[[Chlorthalidone]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Cholesteryl ester storage disease]]
*[[Chronic kidney disease]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Chronic renal insufficiency]]
*[[high chylomicron|Chylomicron levels raised (plasma)]]
*[[Clomiphene]]
*[[colesevelam|Colesevelam hydrochloride]]
*[[Colestyramine]]
*[[Combined oral contraceptive pill]]
*[[congenital generalized lipodystrophy|Congenital generalized lipodystrophy type 1]]
*[[Cushing's syndrome]]
*[[apolipoprotein C2|Deficiency of apolipoprotein C2 ]]
*[[Desvenlafaxine]]
*[[Diabetes mellitus]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
{{col-break|width=33%}}
*[[Diuretics]]
*[[Estrogen replacement therapy]]
*[[Familial chylomicronemia]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Familial combined hyperlipidemia]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Familial histiocytic reticulosis]]
*[[Familial hypertriglyceridemia]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Fish eye disease]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Fosamprenavir]]
*[[Glucocorticoids]]
*[[glycogen storage disease|Glycogen storage disease type 1]]
*[[Glycogenosis type 1a]]
*[[carbohydrate|High carbohydrate or high glycemic index]]
*[[Hydrochlorothiazide]]
*[[hyperlipoproteinemia type V|Hyperlipoproteinemia, familial type 5]]<ref name="pmid1078394">{{cite journal| author=Fallat RW, Glueck CJ| title=Familial and acquired type V hyperlipoproteinemia. | journal=Atherosclerosis | year= 1976 | volume= 23 | issue= 1 | pages= 41-62 | pmid=1078394 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1078394 }} </ref>
*[[Hypothyroidism]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Insulin resistance]]
*[[Interferon alpha]]
*[[IDL|Intermediate density lipoprotein levels raised (plasma or serum)]]
*[[Lecithin cholesterol acyltransferase deficiency]]
*[[Linagliptin]]
*[[Lipodystrophy]]
*[[Lipoprotein lipase deficiency]]
*[[Liver cirrhosis]]
*[[Lopinavir]]
*[[Macrophage activation syndrome]]
*[[Metabolic syndrome]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
{{col-break|width=33%}}
*[[Mirtazapine]]
*[[Nephrotic syndrome]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Niemann-Pick disease|Niemann-Pick disease type B]]
*[[Non-alcoholic fatty liver disease]]
*[[Non-nucleoside reverse transcriptase inhibitors]]
*[[Obesity]]<ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Olanzapine]]
*[[isotretinoin|Oral isotretinoin]]
*[[Paraproteinemias]]
*[[Parenteral nutrition]]
*[[Polycystic ovary syndrome]]
*[[Pregnancy]]
*[[Propofol]]
*[[Protease inhibitors]]
*[[reaven syndrome|Reaven syndrome X]]
*[[Ritonavir]]
*[[Saquinavir]]
*[[Sphingomyelinase deficiency]]
*[[Systemic lupus erythematosus]]
*[[Tamoxifen]]
*[[Tangier disease]] <ref name="pmid19355858">{{cite journal| author=Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP| title=Primary and secondary hypertriglyceridaemia. | journal=Curr Drug Targets | year= 2009 | volume= 10 | issue= 4 | pages= 336-43 | pmid=19355858 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19355858 }} </ref>
*[[Temsirolimus]]
*[[Tipranavir]]
*[[Tocilizumab]]
*[[VLDL|Very low density lipoprotein levels raised (plasma or serum)]]
*[[vitamin E deficiency|Vitamin E deficiency, familial isolated]]
{{col-end}}


===Combined List of Causes in Alphabetical Order===
===Combined List of Causes in Alphabetical Order===

Revision as of 21:21, 13 November 2013

Lipoprotein Disorders Main Page

Hyperlipoproteinemia Microchapters

Hypercholesterolemia Patient Information

Hypertriglyceridemia Patient Information

Overview

Classification

Familial hyperchylomicronemia
Familial hypercholesterolemia
Familial combined hyperlipidemia
Dysbetalipoproteinemia
Primary hypertriglyceridemia
Mixed hyperlipoproteinemia

Differential Diagnosis

Screening

ACC/AHA Guideline Recommendations

Summary

Treatment

Major recommendations for statin therapy

Therapeutic response to statin therapy

Blood cholesterol LDL and non-HDL treatment goals

Treatment in heart failure and hemodialysis

Primary prevention

Secondary prevention

Intensity of statin therapy in primary and secondary prevention

Safety Recommendations

Guideline on Lifestyle Management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes based on Major Lipoprotein Detected in Blood Laboratory Test

High Chylomicron Causes

High Chylomicron Remnant Causes

High HDL Causes

High IDL Causes

High LDL Causes

High VLDL Causes

High Total Cholesterol Causes

High Triglyceride Causes

Combined List of Causes in Alphabetical Order

References

  1. ↑ Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995). "Effects of antihypertensive therapy on serum lipids". Ann Intern Med. 122 (2): 133–41. PMID 7992988.
  2. ↑ Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE; et al. (2003). "Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis". Ann Rheum Dis. 62 (9): 842–5. PMC 1754645. PMID 12922956.
  3. ↑ 3.0 3.1 3.2 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter |month= ignored (help)
  4. ↑ Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH; et al. (1992). "Familial lipoprotein disorders in patients with premature coronary artery disease". Circulation. 85 (6): 2025–33. PMID 1534286.
  5. ↑ 5.0 5.1 5.2 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter |month= ignored (help)
  6. ↑ 6.0 6.1 Yoshimura, T.; Ito, M.; Sakoda, Y.; Kobori, S.; Okamura, H. (1998). "Rare case of autoimmune hyperchylomicronemia during pregnancy". Eur J Obstet Gynecol Reprod Biol. 76 (1): 49–51. PMID 9481547. Unknown parameter |month= ignored (help)
  7. ↑ Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S; et al. (1992). "Severe defect in clearing postprandial chylomicron remnants in dialysis patients". Kidney Int. 42 (5): 1247–52. PMID 1453610.
  8. ↑ Ito M, Takamatsu J, Matsuo T, Kameoka K, Kubota S, Fukata S; et al. (2003). "Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement". Clin Endocrinol (Oxf). 58 (5): 621–6. PMID 12699445.
  9. ↑ Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS; et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis. 187 (1): 116–22. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.
  10. ↑ Brasaemle DL, Cornely-Moss K, Bensadoun A (1993). "Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E." J Lipid Res. 34 (3): 455–65. PMID 8468529.
  11. ↑ Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
  12. ↑ 12.0 12.1 12.2 Nishizawa Y, Shoji T, Kawagishi T, Morii H (1997). "Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation". Kidney Int Suppl. 62: S90–2. PMID 9350691.
  13. ↑ Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T (1999). "Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients". Kidney Int Suppl. 71: S227–8. PMID 10412783.
  14. ↑ Durrington PN (1993). "Diabetes, hypertension and hyperlipidaemia". Postgrad Med J. 69 Suppl 1: S18–25, discussion S25-9. PMID 8497453.
  15. ↑ Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T; et al. (2001). "Atherogenic lipoprotein changes in diabetic nephropathy". Atherosclerosis. 156 (2): 425–33. PMID 11395040.
  16. ↑ Geberhiwot T, Alger S, McKiernan P, Packard C, Caslake M, Elias E; et al. (2007). "Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX". J Inherit Metab Dis. 30 (3): 406. doi:10.1007/s10545-007-0485-2. PMID 17407002.
  17. ↑ Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G, Letarte J (1988). "Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding". J Lipid Res. 29 (2): 215–26. PMID 3130454.
  18. ↑ Pejic, RN.; Lee, DT. "Hypertriglyceridemia". J Am Board Fam Med. 19 (3): 310–6. PMID 16672684.
  19. ↑ 19.0 19.1 Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter |month= ignored (help)
  20. ↑ 20.00 20.01 20.02 20.03 20.04 20.05 20.06 20.07 20.08 20.09 20.10 20.11 20.12 20.13 Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP (2009). "Primary and secondary hypertriglyceridaemia". Curr Drug Targets. 10 (4): 336–43. PMID 19355858.
  21. ↑ Fallat RW, Glueck CJ (1976). "Familial and acquired type V hyperlipoproteinemia". Atherosclerosis. 23 (1): 41–62. PMID 1078394.
Retrieved from "https://www.wikidoc.org/index.php?title=Hyperlipoproteinemia_causes&oldid=912718"